Mental health care utilization among men with castration-resistant prostate cancer receiving abiraterone or enzalutamide.
Mental health care utilization among men with castration-resistant prostate cancer receiving abiraterone or enzalutamide.
复制标题
DOI：
10.1002/cam4.6237
复制
发表时间：
2023-08
期刊：
影响因子：
4
通讯作者：
Caram, Megan E. V.
中科院分区：
文献类型：
--
作者：
Tsao, Phoebe A.;Burns, Jennifer;Kumbier, Kyle;Sparks, Jordan B.;Entenman, Shami;Bloor, Lindsey E.;Bohnert, Amy S. B.;Skolarus, Ted A.;Caram, Megan E. V.
阿比特龙和Enzalutamide是去势抵抗性前列腺癌（CRPC）治疗药物，由于其抗雄激素靶点不同，与精神健康症状可能存在明显相关性。我们使用国家退伍军人健康管理局的数据来确定2010年至2017年接受一线阿比特龙或Enzalutamide治疗的CRPC患者。使用泊松回归，我们比较了阿比特龙和enzalutamide队列之间每100患者月的门诊精神健康事件，调整了患者因素（例如，年龄）。我们使用McNemar测试比较了治疗前一年与治疗后一年的心理健康状况。我们确定了2902例接受阿比特龙（n = 1992）或Enzalutamide（n = 910）治疗的CRPC患者。我们发现两组之间的门诊心理健康接触没有差异（调整后的发病率比[aIRR] 1.04，95%置信区间[CI] 0.95-1.15）。然而，有既存精神健康诊断的男性接受了81.3%的门诊精神健康就诊，并且Enzalutamide的此类就诊率更高（aIRR 1.21，95% CI 1.09-1.34）。在开始阿比特龙（n = 1139）或enzalutamide（n = 446）治疗前后入组≥1年的患者中，开始治疗前后的精神卫生保健利用率无差异（17.0%患者vs. 17.6%，p = 0.60，阿比特龙; 16.4% vs. 18.4%，p = 0.26，enzalutamide）。我们发现接受一线阿比特龙与Enzalutamide治疗的CRPC患者之间的精神卫生保健利用率没有总体差异。然而，既往有精神健康诊断的男性接受了大部分精神健康护理，并且接受enzalutamide治疗的精神健康访视更多。在这项在退伍军人健康管理局接受治疗的去势抵抗性前列腺癌男性的回顾性队列研究中，接受一线阿比特龙与Enzalutamide治疗的患者之间的精神卫生保健利用率没有总体差异。然而，既往有精神健康诊断的男性接受了大部分精神健康护理，并且接受enzalutamide治疗的精神健康访视更多。
Abiraterone and enzalutamide are castration‐resistant prostate cancer (CRPC) therapies with potentially distinct associations with mental health symptoms given their differing antiandrogen targets. We used national Veterans Health Administration data to identify patients with CRPC who received first‐line abiraterone or enzalutamide from 2010 to 2017. Using Poisson regression, we compared outpatient mental health encounters per 100 patient‐months on drug between the abiraterone and enzalutamide cohorts adjusting for patient factors (e.g., age). We compared mental health encounters in the year before versus after starting therapy using the McNemar test. We identified 2902 CRPC patients who received abiraterone (n = 1992) or enzalutamide (n = 910). We found no difference in outpatient mental health encounters between the two groups (adjusted incident rate ratio [aIRR] 1.04, 95% confidence interval [CI] 0.95–1.15). However, men with preexisting mental health diagnoses received 81.3% of the outpatient mental health encounters and had higher rates of these encounters with enzalutamide (aIRR 1.21, 95% CI 1.09–1.34). Among patients with ≥1 year of enrollment before and after starting abiraterone (n = 1139) or enzalutamide (n = 446), there was no difference in mental health care utilization before versus after starting treatment (17.0% of patients vs. 17.6%, p = 0.60, abiraterone; 16.4% vs. 18.4%, p = 0.26, enzalutamide). We found no overall differences in mental health care utilization between CRPC patients who received first‐line abiraterone versus enzalutamide. However, men with preexisting mental health diagnoses received the majority of mental health care and had more mental health visits with enzalutamide. In this retrospective cohort study of men with castration‐resistant prostate cancer who received their care in the Veterans Health Administration, there was no overall difference in mental health care utilization between those who received first‐line abiraterone versus enzalutamide. However, men with preexisting mental health diagnoses received the majority of mental health care and had more mental health visits with enzalutamide.
登录
查看更多内容
影响因子：
158.5
作者：
Parker, C.;Nilsson, S.;Sartor, O.
通讯作者：
Sartor, O.
影响因子：
3.2
作者：
Shore, Neal D.;Saltzstein, Daniel;McGowan, Tracy
通讯作者：
McGowan, Tracy
影响因子：
158.5
作者：
Kantoff, Philip W.;Higano, Celestia S.;Young, J.
通讯作者：
Young, J.
DOI：
10.1056/nejmoa1702900
发表时间：
2017-07-27
期刊：
The New England journal of medicine
影响因子：
--
作者：
James ND;de Bono JS;Spears MR;Clarke NW;Mason MD;Dearnaley DP;Ritchie AWS;Amos CL;Gilson C;Jones RJ;Matheson D;Millman R;Attard G;Chowdhury S;Cross WR;Gillessen S;Parker CC;Russell JM;Berthold DR;Brawley C;Adab F;Aung S;Birtle AJ;Bowen J;Brock S;Chakraborti P;Ferguson C;Gale J;Gray E;Hingorani M;Hoskin PJ;Lester JF;Malik ZI;McKinna F;McPhail N;Money-Kyrle J;O'Sullivan J;Parikh O;Protheroe A;Robinson A;Srihari NN;Thomas C;Wagstaff J;Wylie J;Zarkar A;Parmar MKB;Sydes MR;STAMPEDE Investigators
通讯作者：
STAMPEDE Investigators
影响因子：
10.3
作者：
Lai, Lillian Y.;Oerline, Mary K.;Shahinian, Vahakn B.
通讯作者：
Shahinian, Vahakn B.